Latest Articles
- ArticleThe Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple SclerosisAna Cirac, Thanos Tsaktanis, Tobias Beyer, et al.July 23, 2021
- ArticleDysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson DiseaseZhaoqi Yan, Wei Yang, Hairong Wei, et al.July 22, 2021
- ArticleInternational Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody EncephalitisMargherita Nosadini, Terrence Thomas, Michael Eyre, et al.July 22, 2021
- ArticlePredicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated SyndromeEnric Monreal, Susana Sainz de la Maza, Lucienne Costa-Frossard, et al.July 22, 2021
- ArticleObesity in Pediatric-Onset Multiple SclerosisA French Cohort StudyPauline Milles, Gianpaolo De Filippo, Hélène Maurey, et al.July 20, 2021
- ArticleParaneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With TeratomaA Case Report and Literature ReviewRyotaro Ikeguchi, Yuko Shimizu, Ayato Shimomura, et al.July 20, 2021
- ArticleSerum Contactin-1 in CIDPA Cross-Sectional StudyLuuk Wieske, Lorena Martín-Aguilar, Janev Fehmi, et al.July 20, 2021
- Clinical/Scientific NotesCombined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal LeukoencephalopathyA Case ReportRebecca Wicklein, Simon Heidegger, Mareike Verbeek, et al.July 20, 2021
- ArticleOcrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.July 14, 2021
Pages
Advertisement